PDCD1 and breast cancer: Although immunotherapy, such as PD ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) blockade therapy, contributes to curative effectiveness in advanced BC, a low response rate still limits the clinical benefit (Ott et al., 2020; Patel et al., 2020).